SLDB — Solid Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $334.03m
- $186.34m
Annual cashflow statement for Solid Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -88.3 | -72.2 | -86 | -96 | -125 |
| Depreciation | |||||
| Non-Cash Items | 11.6 | 14.5 | -10.7 | 5.59 | 19.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.2 | -23 | -3.69 | -6.34 | 2.85 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -56.6 | -77.8 | -98 | -94.2 | -100 |
| Capital Expenditures | -0.899 | -1.28 | -3.02 | -1.51 | -0.654 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 7.5 | -89.8 | 62.2 | 11.2 | -15.4 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 6.6 | -91.1 | 59.2 | 9.69 | -16.1 |
| Financing Cash Flow Items | -3.79 | 0.066 | 2.28 | 0.148 | -4.77 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 129 | 135 | 74.8 | 3.12 | 122 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 78.7 | -33.9 | 36 | -81.4 | 6.34 |